不同终末期肝病模型评分的肝硬化患者肝胆期:钆贝葡胺与钆塞酸二钠增强MRI性能比较
该回顾性横截面研究分析了249例肝硬化患者的131次钆贝葡胺增强MRI和127次钆塞酸二钠增强MRI,比较肝胆期图像质量与MELD评分的关系。钆塞酸二钠组肝胆期充分性的比值比为3.64(p<0.001),且随MELD评分升高优势增大(交互项exp(b)=1.233;p=0.011)。结论认为钆塞酸二钠增强MRI的肝胆期质量优于钆贝葡胺,尤其在高MELD评分患者。
要点
- 肝硬化患者中,钆塞酸二钠增强MRI的肝胆期充分性优于钆贝葡胺增强MRI。
- MELD评分>10且临床需要肝胆期时,应优先选择钆塞酸二钠增强MRI。
- MELD评分>15时,使用肝胆特异性对比剂可能无益;若临床需要,作者推荐使用钆塞酸二钠。
核心结论
- 肝硬化患者中,钆塞酸二钠增强MRI获得的肝胆期质量优于钆贝葡胺增强MRI,主要见于高MELD评分患者。
研究设计与样本
- 回顾性横截面研究,纳入249例肝硬化患者(181男,68女;平均年龄64.8岁)的131次钆贝葡胺增强MRI和127次钆塞酸二钠增强MRI,检查时间2011年8月至2017年4月;计算肝实质对比增强指数并与MELD评分行多元线性回归分析,对肝胆期充分性行校正MELD评分的logistic回归分析。
诊断标准与关键数值
- 钆塞酸二钠组与钆贝葡胺组相比,相同MELD评分下对比增强指数增加因子为0.23(p<0.001);获得充分肝胆期的平均比值比为3.64(p<0.001);肝胆期充分性随MELD评分升高的交互项exp(b)=1.233(p=0.011)。
临床应用与阅片要点
- 作者认为,MELD评分>10的肝硬化患者若临床需要肝胆期,应优先选择钆塞酸二钠增强MRI;MELD评分>15时使用肝胆特异性对比剂可能无益,但若临床需要,作者推荐使用钆塞酸二钠以获得临床相关信息的更高概率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to compare the performance of gadobenate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI in the hepatobiliary phase (HBP) in cirrhotic patients with different degrees of liver dysfunction.
METHODS: In this retrospective cross-sectional study, we analyzed the unenhanced phase and the HBP of 131 gadobenate dimeglumine-enhanced MRI examinations (gadobenate dimeglumine group) and 127 gadoxetic acid-enhanced MRI examinations (gadoxetic acid group) performed in 249 cirrhotic patients (181 men and 68 women; mean age, 64.8 years) from August 2011 to April 2017. For each MRI, the contrast enhancement index of the liver parenchyma was calculated and correlated to the Model For End-Stage Liver Disease (MELD) score (multiple linear regression analysis). A qualitative analysis of the adequacy of the HBP, adjusted for the MELD score (logistic regression analysis), was performed.
RESULTS: The contrast enhancement index was inversely related (r = - 0.013) with MELD score in both gadoxetic acid and gadobenate dimeglumine group. At the same MELD score, the contrast enhancement index in the gadoxetic acid group was increased by a factor of 0.23 compared to the gadobenate dimeglumine group (p < 0.001), and the mean odds ratio to have an adequate HBP with gadoxetic acid compared to gadobenate dimeglumine was 3.64 (p < 0.001). The adequacy of the HBP in the gadoxetic acid group compared to the gadobenate dimeglumine group increased with the increase of the MELD score (exp(b)interaction = 1.233; p = 0.011).
CONCLUSION: In cirrhotic patients, the hepatobiliary phase obtained with gadoxetic acid-enhanced MRI is of better quality in comparison to gadobenate dimeglumine-enhanced MRI, mainly in patients with high MELD score.
KEY POINTS: • In cirrhotic patients, the adequacy of the hepatobiliary phase with gadoxetic acid-enhanced MRI is better compared to gadobenate dimeglumine-enhanced MRI. • Gadoxetic acid-enhanced MRI should be preferred to gadobenate dimeglumine-enhanced MRI in cirrhotic patients with MELD score > 10, if the hepatobiliary phase is clinically indicated. • In patients with high MELD score (> 15), the administration of the hepatobiliary agent could be useless; even though, if it is clinically indicated, we recommend to use gadoxetic acid given the higher probability of obtaining clinically relevant information.
引用
- Khouri Chalouhi C, Vernuccio F, Rini F, et al. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine. Eur Radiol. 2018. PMID: 30547205. doi:10.1007/s00330-018-5884-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。